Claire Mulot
Overview
Explore the profile of Claire Mulot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
3441
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gallois C, Sroussi M, Andre T, Mouillet-Richard S, Agueeff N, Mulot C, et al.
J Clin Oncol
. 2025 Jan;
:JCO2302262.
PMID: 39889251
Purpose: The objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis of transcriptomic signatures of the tumor microenvironment (TME) and cell...
2.
Pilati C, Soulabaille A, Gallois C, Blons H, Cayre A, Sroussi M, et al.
Gastroenterology
. 2024 Nov;
PMID: 39612956
Background & Aims: ERBB2 pathway activation, through amplification or activating mutations, represents a new target for colon cancer (CC) treatment. Molecular methods were compared with the gold standard for assessing...
3.
Middha P, Wang X, Behrens S, Bolla M, Wang Q, Dennis J, et al.
Breast Cancer Res
. 2023 Aug;
25(1):93.
PMID: 37559094
Background: Genome-wide studies of gene-environment interactions (G×E) may identify variants associated with disease risk in conjunction with lifestyle/environmental exposures. We conducted a genome-wide G×E analysis of ~ 7.6 million common...
4.
Naour J, Montegut L, Pan Y, Scuderi S, Cordier P, Joseph A, et al.
Oncoimmunology
. 2023 Jul;
12(1):2237354.
PMID: 37492227
Formyl peptide receptor-1 (FPR1) is a pattern recognition receptor that is mostly expressed by myeloid cells. In patients with colorectal cancer (CRC), a loss-of-function polymorphism (rs867228) in the gene coding...
5.
de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, et al.
Ther Adv Med Oncol
. 2023 Jan;
14:17588359221141307.
PMID: 36601631
Background: Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor () pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC),...
6.
Grancher A, Beaussire L, Manfredi S, Le Malicot K, Dutherage M, Verdier V, et al.
Front Oncol
. 2022 Nov;
12:973167.
PMID: 36439476
Circulating tumor DNA (ctDNA) is reported to be promising in localized colorectal cancer (CRC). The present study aimed to retrospectively evaluate the impact of ctDNA in patients with a resected...
7.
Wang X, Middha Kapoor P, Auer P, Dennis J, Dunning A, Wang Q, et al.
Sci Rep
. 2022 Apr;
12(1):6199.
PMID: 35418701
Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted...
8.
Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer
Beinse G, LE Frere Belda M, Just P, Bekmezian N, Koual M, Garinet S, et al.
Gynecol Oncol
. 2022 Jan;
164(3):596-606.
PMID: 35033379
Background: Despite recent advances in endometrial carcinoma (EC) molecular characterization, its prognostication remains challenging. We aimed to assess whether RNAseq could stratify EC patient prognosis beyond current classification systems. Methods:...
9.
Pietrasz D, Wang-Renault S, Taieb J, Dahan L, Postel M, Durand-Labrunie J, et al.
Br J Cancer
. 2021 Nov;
126(3):440-448.
PMID: 34811505
Objective: The prognostication of metastatic pancreatic adenocarcinoma (mPDAC) patients remains uncertain, mainly based on carbohydrate antigen 19-9 (CA19-9), with limited utility. Circulating tumour DNA (ctDNA) has been suggested as a...
10.
Benhaim L, Bouche O, Normand C, Didelot A, Mulot C, Le Corre D, et al.
Eur J Cancer
. 2021 Nov;
159:24-33.
PMID: 34731746
Background: In non-metastatic colorectal cancer (CRC), we evaluated prospectively the pertinence of longitudinal detection and quantification of circulating tumor DNA (ctDNA) as a prognostic marker of recurrence. Method: The presence...